Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Acton takes over US rights to Nasacort HFA from Sanofi US

Executive Summary

Acton Pharmaceuticals Inc. (respiratory therapeutics) has licensed exclusive US rights to Sanofi US’s aerosol nasal allergy treatment Nasacort HFA (triamcinolone acetonide). Financial terms were not disclosed, but Sanofi states that it retains all rights to its already marketed aqueous form Nasacort AQ.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies